Keisuke Mitsuoka

641 total citations
18 papers, 540 citations indexed

About

Keisuke Mitsuoka is a scholar working on Oncology, Molecular Biology and Biochemistry. According to data from OpenAlex, Keisuke Mitsuoka has authored 18 papers receiving a total of 540 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Molecular Biology and 4 papers in Biochemistry. Recurrent topics in Keisuke Mitsuoka's work include Drug Transport and Resistance Mechanisms (7 papers), Amino Acid Enzymes and Metabolism (4 papers) and Medical Imaging Techniques and Applications (3 papers). Keisuke Mitsuoka is often cited by papers focused on Drug Transport and Resistance Mechanisms (7 papers), Amino Acid Enzymes and Metabolism (4 papers) and Medical Imaging Techniques and Applications (3 papers). Keisuke Mitsuoka collaborates with scholars based in Japan, Netherlands and United States. Keisuke Mitsuoka's co-authors include Sosuke Miyoshi, Yukio Kato, Ikumi Tamai, Akira Tsuji, Per Artursson, Yoshimichi Sai, Yosuke Kaneko, Satsuki Ito, Masao Sasamata and Yuka Hayashizaki and has published in prestigious journals such as Blood, Clinical Cancer Research and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Keisuke Mitsuoka

18 papers receiving 527 citations

Peers

Keisuke Mitsuoka

ONCOL

EDM

SURGE

PPCH

Chizuru Watanabe Japan

Cynthia Cline United States

Tomoaki Higuchi Japan

KehDih Lai Canada

Françoise Goirand France

Zhengwen Jiang China

Kathleen A. Hopp United States

Jamie L. Resnik United States

Jung Yeon Ghee South Korea

Hidde H. Huidekoper Netherlands

Chizuru Watanabe Japan

Keisuke Mitsuoka

126 ×0.6

ONCOL

196 ×1.0

240 ×1.5

EDM

144 ×1.5

SURGE

30 ×0.4

PPCH

Citations per year, relative to Keisuke Mitsuoka Keisuke Mitsuoka (= 1×) peers Chizuru Watanabe

Countries citing papers authored by Keisuke Mitsuoka

Since Specialization

Citations

This map shows the geographic impact of Keisuke Mitsuoka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keisuke Mitsuoka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keisuke Mitsuoka more than expected).

Fields of papers citing papers by Keisuke Mitsuoka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keisuke Mitsuoka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keisuke Mitsuoka. The network helps show where Keisuke Mitsuoka may publish in the future.

Co-authorship network of co-authors of Keisuke Mitsuoka

This figure shows the co-authorship network connecting the top 25 collaborators of Keisuke Mitsuoka. A scholar is included among the top collaborators of Keisuke Mitsuoka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keisuke Mitsuoka. Keisuke Mitsuoka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Mitsuoka, Keisuke, Aya Kita, Yoshihiro Murakami, et al.. (2018). Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [11C]YM155. Nuclear Medicine and Biology. 64-65. 41–46. 2 indexed citations

Mitsuoka, Keisuke, Yuka Hayashizaki, Yoshihiro Murakami, et al.. (2016). Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using ¹¹C‐MDG. Pharmacology Research & Perspectives. 4(4). e00244–e00244. 6 indexed citations

Kaneko, Naoki, Keisuke Mitsuoka, Nobuaki Amino, et al.. (2014). Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma. Clinical Cancer Research. 20(7). 1814–1822. 36 indexed citations

Yokono, Masanori, Toshiyuki Takasu, Yuka Hayashizaki, et al.. (2014). SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. European Journal of Pharmacology. 727. 66–74. 171 indexed citations

Mitsuoka, Keisuke, et al.. (2013). [18F]FDG-PET as an Imaging Biomarker to NMDA Receptor Antagonist-Induced Neurotoxicity. Toxicological Sciences. 133(1). 13–21. 10 indexed citations

Fushiki, Hiroshi, Sosuke Miyoshi, Akihiro Noda, et al.. (2013). Pre-clinical validation of orthotopically-implanted pulmonary tumor by imaging with 18F-fluorothymidine-positron emission tomography/computed tomography.. PubMed. 33(11). 4741–9. 7 indexed citations

Kita, Aya, Keisuke Mitsuoka, Naoki Kaneko, et al.. (2012). Sepantronium Bromide (YM155) Enhances Response of Human B-Cell Non-Hodgkin Lymphoma to Rituximab. Journal of Pharmacology and Experimental Therapeutics. 343(1). 178–183. 26 indexed citations

Murakami, Yoshihiro, Aya Kita, Kentaro Yamanaka, et al.. (2012). Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model. Nuclear Medicine and Biology. 40(2). 221–226. 12 indexed citations

Kita, Aya, Takahito Nakahara, Masahiro Takeuchi, et al.. (2010). Survivin supressant: a promising target for cancer therapy and pharmacological profiles of YM155. Folia Pharmacologica Japonica. 136(4). 198–203. 6 indexed citations

10.

Mitsuoka, Keisuke, Yukio Kato, Sosuke Miyoshi, et al.. (2010). Inhibition of oligopeptide transporter suppress growth of human pancreatic cancer cells. European Journal of Pharmaceutical Sciences. 40(3). 202–208. 26 indexed citations

11.

Nakanishi, Takeo, Douglas D. Ross, & Keisuke Mitsuoka. (2010). Methods to Evaluate Transporter Activity in Cancer. Methods in molecular biology. 637. 105–120. 8 indexed citations

12.

Nakakariya, Masanori, et al.. (2009). Organic anion transporter OAT1 is involved in renal handling of citrulline. American Journal of Physiology-Renal Physiology. 297(1). F71–F79. 22 indexed citations

13.

Mitsuoka, Keisuke, Ikumi Tamai, Yoshiyuki Kubo, et al.. (2009). Direct Evidence for Efficient Transport and Minimal Metabolism of L-Cephalexin by Oligopeptide Transporter 1 in Budded Baculovirus Fraction. Biological and Pharmaceutical Bulletin. 32(8). 1459–1461. 2 indexed citations

14.

Nakahara, Takahito, Aya Kita, Keisuke Mitsuoka, et al.. (2009). YM155, a Novel Survivin Suppressant, Improves the Antitumor Effect of Rituximab and Rituximab-Containing Regimens in Diffuse Large B Cell Lymphoma (DLBCL) Xenograft Mouse Models.. Blood. 114(22). 2718–2718. 2 indexed citations

15.

Mitsuoka, Keisuke, Yoshiyuki Shirasaka, Masanobu Sato, et al.. (2009). Transport characteristics of L‐citrulline in renal apical membrane of proximal tubular cells. Biopharmaceutics & Drug Disposition. 30(3). 126–137. 17 indexed citations

16.

Mitsuoka, Keisuke, Sosuke Miyoshi, Yukio Kato, et al.. (2008). Cancer Detection Using a PET Tracer, ¹¹ C-Glycylsarcosine, Targeted to H ⁺ /Peptide Transporter. Journal of Nuclear Medicine. 49(4). 615–622. 39 indexed citations

17.

Mitsuoka, Keisuke, Yukio Kato, Yoshiyuki Kubo, & Akira Tsuji. (2006). Functional Expression of Stereoselective Metabolism of Cephalexin by Exogenous Transfection of Oligopeptide Transporter PEPT1. Drug Metabolism and Disposition. 35(3). 356–362. 8 indexed citations

18.

Sai, Yoshimichi, Yosuke Kaneko, Satsuki Ito, et al.. (2006). PREDOMINANT CONTRIBUTION OF ORGANIC ANION TRANSPORTING POLYPEPTIDE OATP-B (OATP2B1) TO APICAL UPTAKE OF ESTRONE-3-SULFATE BY HUMAN INTESTINAL CACO-2 CELLS. Drug Metabolism and Disposition. 34(8). 1423–1431. 140 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact